Skip to main content
Premium Trial:

Request an Annual Quote

OncoTyrol to Conduct Validation Studies on Protagen UniArray Technology

NEW YORK (GenomeWeb News) – Protagen said today that it has formed a collaboration with OncoTyrol to conduct validation studies on the firm's UniArray technology platform.

The study aims to determine the "most robust combination of putative prostate cancer markers and optimizing the diagnostic protein biochip to proceed to clinical trials," Protagen CEO Stefan Müllner said in a statement.

Protagen said that it recently identified autoantigen candidates in the serum of patients with prostate cancer using its UniArray technology platform. The Dortmund, Germany-based firm hopes to develop a test targeting the intermediate patient risk group, which includes individuals with a PSA range of between 2.5 ng/ml and 4.0 ng/ml.

OncoTyrol is the K1 project for Personalized Cancer Medicine and includes a consortium of researchers at the Biomedical Campus Innsbruck as well as researchers from national and international academic and industrial partners.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.